APL, in addition to confirming a negative prognostic impact, we also showed significant associations with younger age, male gender and presentation leucocyte count. High leucocyte count (410 Â 10 9 /l) has been consistently demonstrated to be associated with an inferior DFS.
/l) and high risk (leucocyte count X10 Â 10 9 /l) patients would receive more intensive treatment. The strategy has resulted in much improved outcome in intermediate-and high-risk APL. Interestingly, we showed that CDKN2B methylation was independent of and more powerful than presentation leucocyte count as a prognostic indicator, implying that CDKN2B methylation might be incorporated as part of the algorithm in risk-adjusted treatment of newly diagnosed APL.
CDKN2B methylation is the only molecular marker consistently shown to be of prognostic significance. Previous studies had suggested that the short PML/RARA transcript might be prognostically relevant. 1 However, later studies have not confirmed this finding. FLT3 gene mutations/duplications have also been implicated as negative prognostic markers, 6 and FLT3 antagonists have been suggested to be therapeutically useful. On the contrary, recent studies have shown that the apparent negative impact of FLT3 aberrations is due to their association with high leucocyte count. 7 In this context, as pharmacological grade demethylating agents such as 5-azacytidine and decitabine are available, the possibility of incorporating demethylation in the treatment strategy of APL might have to be explored.
Finally, CDKN2B methylation did not impact on OS. This might be due to the high efficacy of As 2 O 3 for salvage of relapses. Indeed, we have recently shown that CDKN2B methylation is unrelated to the outcome of relapsed APL treated with As 2 O 3 . 8 Nevertheless, the definition of CDKN2B methylation in newly diagnosed APL leading to optimal therapy and prevention of relapse is still crucial, as a relapse invariably means more treatment, with increases of long-term complications that may curtail patient survival. NF1 tumor suppressor gene loss-of-function causes NF1 syndrome-associated myeloid malignancies, particularly juvenile myelomonocytic leukemia (JMML), which can undergo transformation to an acute leukemia. The NF1 gene protein product, neurofibromin, is a GTPase-activating protein (GAP) with activity for N-, K-, H-and R-RAS proteins and as such is a negative regulator of Ras signaling. Loss of NF1 in JMML cells may be functionally equivalent to an activating RAS gene point mutation, since these genetic events are mutually exclusive in this disease. Mouse modeling studies demonstrate that Nf1 gene loss in hematopoietic cells can cause myeloid malignancy. 3, 4 Unfortunately, NF1-associated leukemias, such as JMML, tend to have a poor prognosis. 4 The response of Nf1-deficient AML to Ara-C treatment has not been examined yet.
BXH-2 strain mice spontaneously develop AML with a high incidence within 1 year of age, due to insertional mutagenesis by an ecotropic MuLV retrovirus. We have established and characterized AML cell lines from BXH-2 leukemia, including those with biallelic loss of the Nf1 gene. 3 Owing to their
Cell line Nf1 deficiency confers Ara-C resistance via increased MEK activity. (a) The Nf1 status, MEK activity and Ara-C response in BXH-2 AML cell lines. The Nf1 status (À: deficiency; þ : wild type) was determined before. 2 The Ara-C IC 50 (ng/ml) was measured using MTS assay according to the instruction with the kit (Promega Co., WI, USA). The U0126 sensitivity (Y: sensitive; N: nonsensitive; À: not done) was indicated as 'U0126-Sen.'. The basal levels of candidate proteins in the indicated AML cell lines were determined by Western blot. The relative strength of signal for phosphorylated ERK was quantified using program Scion Image and normalized to that for ERK1/2, as shown below the p-ERK panel.
(b) Overexpression of NF1-GRD was detected by RT-PCR in the Nf1-deficient cells stably transfected with NF1-GRD ('NF1-GRD'), but not in the control ('Vector'). À: no reverse transcriptase; þ : with reverse transcriptase. Ara-C response in NF1-GRD-expressing cells and control cells were then determined by MTS assay. Representative data from three independent experiments is shown. (c) Nf1-deficient cells, B114 and B117, and neurofibromin-expressing B140, were treated with vehicle ('DMSO'), or Ara-C alone ('Ara-C'), or U0126 alone ('DMSO þ U0126'), or sequentially with Ara-C and U0126 ('Ara-C þ U0126'). Apoptotic nuclei were counted following Hoechst 33342 staining. Asterisks indicate Po0.05 (Student's t-test). (d) The basal level of phosphorylated eIF4E and eIF4E proteins in the NF1-GRD-transfected Nf1-deficient cells B114-GRD ('NF1-GRD') and vector-transfected Nf1-deficient cells B114-vect ('Vector') as a control were examined by Western blot. Effect of rapamycin on Ara-C sensitivity of B114-GRD and B114-vect was determined by MTS assay. Cells were incubated with the escalating doses of Ara-C for 40 h, followed by treatment with the indicated concentrations of rapamycin for further 24 h before MTS reading. Shown here is the result representative of three independent experiments.
Letters to the Editor isogenic background and relative ease of genetic manipulation, we used these AML cell lines to attempt to define the potential genetic determinants of Ara-C resistance in leukemia.
Among the AML cell lines we tested, B106, B114 and B117 all have Nf1-deficiency due to Evi2 proviral insertion. 3 Their Ara-C IC 50 (mean7s.d.) are 210713, 17807130 and 354712 mg/ml, respectively (Figure 1a) , as determined by MTS assay with 72 h of Ara-C exposure. The rest of cell lines, including B132, B139, B140, B162, B186 and B190, have wildtype Nf1, with an Ara-C IC 50 of 18076, 220710, 175710, 16876, 17675 and 18875 mg/ml, respectively (Figure 1a ). There is a significant difference between Nf1-wild-type cells and Nf1-deficient cells in their response to Ara-C treatment, as determined by Student's t-test analysis (Po0.01), indicating an association of Nf1 deficiency in these cells with decreased Ara-C sensitivity. Restoration of Nf1 function with the GAP-related domain of NF1 (NF1-GRD), presently the only known functional domain of Nf1, apparently increased the Ara-C sensitivity (Figure 1b) , suggesting that Ara-C sensitivity of Nf1-deficient leukemia cells can be rescued with NF1-GRD. Thus, Nf1 function can influence Ara-C resistance in AML cells. Leukemias with NF1 mutations usually have a poor prognosis, and strikingly shorter complete remission durations have been noticed in AML patients bearing NF1 or RAS mutations. 5 Although the association between the ATP-binding cassette transporter MDR1/PGP and drug resistance in AML has been well documented, we found no detectable difference in the transcriptional level of Abcb1a, Abcb1b and Abcb4 between sensitive and resistant cells (data not shown). Instead, we found that the level of phosphorylated ERK was elevated in B106, B114 and B117 compared to other BXH-2 AML cell lines tested, but this is not the case for total ERK1/2, p21
Cip1 and p27 (Figure 1a) . Treatment with 1-50 mM U0126, a MEK-specific chemical inhibitor, significantly inhibited ERK activation in B106, B114, B117 and B140 in a dose-dependent manner (data not shown). The U0126 sensitivity of Ara-C response in these cells was determined by exposure of cells to DMSO or 5 mM U0126 for 8 h, followed by treatment with Ara-C for 40 h prior to MTS assay. We found that U0126 significantly decreased Ara-C IC 50 of B106 (124710 mg/ml, compared with 240716 mg/ml for DMSO treatment), B114 (940740 vs 1100753 mg/ml) and B117 (230721 vs 610736 mg/ml), but not in B140 (190714 vs 19078 mg/ml), which has low basal phosphorylated ERK levels (Figure 1a) . Nf1 function rescue with the NF1-GRD domain not only reduced levels of phosphorylated ERK in transfected B114 cells (data not shown) but also made cells more susceptible to cell killing by Ara-C (Figure 1b) . These data suggest that elevated MEK activity in Nf1-deficient leukemia cells confers partial resistance to Ara-C. Furthermore, stimulation with growth factor-enriched WEHI-3-conditioned medium increased MEK activity in B114, and concurrently Ara-C resistance (data not shown). These effects can be reversed by MEK inhibition with U0126 (data not shown), indicating that growth factor stimulation enhances Ara-C resistance by upregulation of MEK activity. This also raises caution in using hematopoietic growth factor-primed chemotherapy of AML, especially for NF1 syndrome-associated AML. Together, these data support the notion that Nf1 loss-induced Ara-C resistance is mediated, in part, by increased MEK pathway activity.
To explore the cellular mechanism of Ara-C resistance, B117 and B140 cells were treated with Ara-C alone or in combination with U0126, followed by cell cycle analysis with PI staining. We did not detect any significant difference in S-phase cell fraction between cells under these treatments. Ara-C-treated B117 and B140 displayed a high percentage of S-phase cells, probably due to the Ara-C-induced S-phase arrest (data not shown). Using Hoechst 33342 staining, we observed that Ara-C treatment caused apoptosis in B114, B117 and B140 cells (Figure 1c) , in a time-dependent manner (data not shown). Importantly, MEK inhibition increased apoptosis in Ara-C-treated leukemia cells with Nf1 deficiency, but not in cells with wild-type Nf1 (Figure 1c) . The ERK pathway has been shown to protect acute promyelocytic leukemia cells from apoptosis induced by arsenic trioxide. These data indicate that Nf1 loss prevents cells from apoptosis by upregulation of MEK activity, which can cause, at least in part, Ara-C resistance.
Interestingly, although there was no detectable difference in total eIF4E level, we found that Nf1-deficient cells displayed increased phosphorylation of eIF4E (Figure 1d, data not shown) . Rapamycin, an inhibitor of the upstream activator of eIF4E, mTOR, increases Ara-C toxicity in Nf1-deficient cell line B114-vect (Figure 1d) . We also observed a similarly sensitizing effect of rapamycin on Nf1-expressing cells (data not shown). However, the NF1-GRD rescued Nf1-deficient cells B114-GRD, when treated with rapamycin, became more sensitive to Ara-C than B114-vect. These data, combined with increased level of phosphorylated eIF4E in B114-GRD, may suggest that eIF4E suppression can reduce Ara-C resistance in Nf1-deficient leukemia cells. The eIF4E protein is necessary for capdependent mRNA translation. Phosphorylation of eIF4E plays a key role in growth and viability, and enhances both its mRNA transport function and its transformation activity in cell culture. Notably, eIF4E has been demonstrated to be important in mediating Akt signaling in drug resistance in vivo. 6 More recently, it has been shown that NF1 deficiency leads to constitutive mTOR signaling, and NF1-deficiency-mediated transformation of mouse embryonic fibroblasts is highly sensitive to the mTOR inhibitor rapamycin. 7 Our data suggest 
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Figure 2
A model: Ara-C resistance conferred by Nf1 loss. Nf1 loss causes hyperactivation of Ras, which stimulates MEK and then ERK activity via Ras-Raf-MEK-ERK pathway. This stimulation may result in the phosphorylation of 4E-BP leading to liberation of eIF-4E, followed by eIF-4E phosphorylation by the kinases Mnk1 and Mnk2, which are activated by ERKs. Activation of eIF4E suppresses Ara-Cinduced cell apoptosis and thus increases Ara-C resistance. This resistance can be partially reversed by blockage of MAPK signaling pathway with MEK-specific inhibitor U0126 or by mTOR-specific inhibitor rapamycin. On the contrary, growth factor stimulation by triggering the RAS pathways enhances resistance to Ara-C. Dashed lines indicate the potential alternative pathways signaling from Nf1 loss to drug resistance.
Letters to the Editor that phosphorylation of eIF4E may be responsible for MEKmediated antiapoptosis in Nf1-deficient cells.
Our results combined with published data support a model depicting Nf1 deficiency leading to Ara-C resistance in AML cells (Figure 2 ). This resistance is mediated by upregulation of MEK and eIF4E activity, which results in enhancement of cell survival to overcome drug-induced apoptosis. This resistance can be reversed experimentally by exposure to a MEK inhibitor or an mTOR inhibitor, or by recovery of Nf1 GRD function. Since our conclusion is drawn based on the analysis of a cell culture model, examining the Ara-C sensitivity of NF1 syndrome-associated leukemia in vivo is needed. MEK-ERK inhibition can selectively suppress leukemia cells but not normal hematopoietic progenitor cells. 8 It may be useful to therapeutically target the MEK pathway or mTOR pathway in combination with Ara-C treatment. Given that a large percentage of myeloid leukemia carries mutations in genes effecting RAS or the RAS pathway, and the clinical outcomes of these patients are generally poor, our findings provide strong rationale for examining the role of dysregulation of components of RAS pathway in Ara-C response.
